Thomas Belcher
Overview
Explore the profile of Thomas Belcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Will I, Stevens E, Belcher T, King K
Mol Ecol
. 2024 Nov;
34(1):e17586.
PMID: 39529601
The frequency of emerging disease is growing with ongoing human activity facilitating new host-pathogen interactions. Novel infection outcomes can also be shaped by the host microbiota. Caenorhabditis elegans nematodes experimentally...
2.
Belcher T, Coutte L, Debrie A, Sencio V, Trottein F, Locht C, et al.
Microbes Infect
. 2024 Aug;
26(8):105404.
PMID: 39128538
Bacterial-viral co-infections are frequent, but their reciprocal effects are not well understood. Here, we examined the effect Bordetella pertussis infection and the role of pertussis toxin (PT) on influenza A...
3.
Belcher T, Rollier C, Dold C, Ross J, MacLennan C
Front Immunol
. 2023 Sep;
14:1248613.
PMID: 37662926
is the causative agent of gonorrhea, a sexually transmitted infection responsible for a major burden of disease with a high global prevalence. Protective immunity to infection is often not observed...
4.
Belcher T, Ait-Yahia S, Solans L, Debrie A, Cauchi S, Tsicopoulos A, et al.
NPJ Vaccines
. 2022 Jun;
7(1):66.
PMID: 35739108
Live attenuated vaccines often have beneficial non-specific effects, protecting against heterologous infectious and non-infectious diseases. We have developed a live attenuated pertussis vaccine, named BPZE1, currently in advanced clinical development....
5.
Belcher T, Dubois V, Rivera-Millot A, Locht C, Jacob-Dubuisson F
Virulence
. 2021 Sep;
12(1):2608-2632.
PMID: 34590541
The highly contagious whooping cough agent has evolved as a human-restricted pathogen from a progenitor which also gave rise to and . While the latter colonizes a broad range of...
6.
Belcher T, Kammoun H, Coutte L, Debrie A, Mielcarek N, Sirard J, et al.
Vaccine
. 2021 Jan;
40(11):1555-1562.
PMID: 33509692
BPZE1 is a live attenuated vaccine against infection by Bordetella pertussis, the causative agent of whooping cough. It was previously shown that BPZE1 provides heterologous protection in mouse models of...
7.
Belcher T, MacArthur I, King J, Langridge G, Mayho M, Parkhill J, et al.
Microb Genom
. 2020 Dec;
6(12).
PMID: 33295860
The identification of genes essential for a bacterium's growth reveals much about its basic physiology under different conditions. , the causative agent of whooping cough, adopts both virulent and avirulent...
8.
MacArthur I, Belcher T, King J, Ramasamy V, Alhammadi M, Preston A
Emerg Microbes Infect
. 2019 Apr;
8(1):603-612.
PMID: 30966996
Whooping cough, or pertussis, is resurgent in numerous countries worldwide. This has renewed interest in Bordetella pertussis biology and vaccinology. The in vitro growth of B. pertussis has been a...
9.
Fyson N, King J, Belcher T, Preston A, Colijn C
PLoS Comput Biol
. 2017 Jul;
13(7):e1005639.
PMID: 28715411
The Gram-negative bacterium Bordetella pertussis is the causative agent of whooping cough, a serious respiratory infection causing hundreds of thousands of deaths annually worldwide. There are effective vaccines, but their...
10.
Sealey K, Belcher T, Preston A
Infect Genet Evol
. 2016 Mar;
40:136-143.
PMID: 26932577
Whooping cough, or pertussis, is resurgent in many countries world-wide. This is linked to switching from the use of whole cell vaccines to acellular vaccines in developed countries. Current evidence...